Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

BRAMESTON 2.5 TABLET 2.5 mg - HSA Drug Approval Details

Approvals/HSA/BRAMESTON 2.5 TABLET 2.5 mg

Approved

THERAPEUTIC

BRAMESTON 2.5 TABLET 2.5 mg

REMEDICA LTD (CYPRUS)🇸🇬 Health Sciences Authority

Approval Date: May 20, 1997
Approval ID: 5f62c317b266ea0e
Company: REMEDICA LTD (CYPRUS)
Type: Therapeutic

Approval Details

Approval Id: 5f62c317b266ea0e
Drug Name: BRAMESTON 2.5 TABLET 2.5 mg
Product Name: BRAMESTON 2.5 TABLET 2.5 mg
Approval Number: SIN09507P
Approval Date: 1997-05-20
Registrant: GOLDPLUS UNIVERSAL PTE LTD
Licence Holder: GOLDPLUS UNIVERSAL PTE LTD
Drug Type: Therapeutic
Forensic Classification: Prescription Only
Dosage Form: TABLET
Route Of Administration: ORAL
Atc Code: G02CB01
Atc Item Name: bromocriptine
Pharma Manufacturer Name: GOLDPLUS UNIVERSAL PTE LTD

Active Ingredients

BROMOCRIPTINE MESYLATE EQV BROMOCRIPTINE

2.5 mg

BROMOCRIPTINE MESYLATE EQV BROMOCRIPTINE

2.5 mg

Approved

Quick Info

Agency

HSA

Country

🇸🇬

Approval Date

May 20, 1997

Approval ID

5f62c317b266ea0e

Type

Therapeutic

Back to HSA Approvals